Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

This study shows that the immune response towards natalizumab, an IgG4 antibody targeting alpha4-integrins, is directed towards the antigen binding site of the drug. This extends previous observations for TNF inhibitors, suggesting that antibodies towards therapeutic antibodies may be inherently neutralizing